소화기 치료제 시장

Global Gastrointestinal Therapeutics Market to Reach US$47.0 Billion by 2032

The global market for Gastrointestinal Therapeutics estimated at US$41.5 Billion in the year 2025, is expected to reach US$47.0 Billion by 2032, growing at a CAGR of 1.8% over the analysis period 2025-2032. Aminosalicylates Drug Class, one of the segments analyzed in the report, is expected to record a 1.3% CAGR and reach US$10.2 Billion by the end of the analysis period. Growth in the Digestive Enzymes Drug Class segment is estimated at 2.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.3 Billion While China is Forecast to Grow at 3.1% CAGR

The Gastrointestinal Therapeutics market in the U.S. is estimated at US$11.3 Billion in the year 2025. China, the world's second largest economy, is forecast to reach a projected market size of US$8.6 Billion by the year 2032 trailing a CAGR of 3.1% over the analysis period 2025-2032. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.9% and 1.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.1% CAGR.

Global Gastrointestinal Therapeutics Market - Key Trends and Drivers Summarized

Why Are Gastrointestinal Therapeutics Essential for Modern Healthcare?

Gastrointestinal (GI) therapeutics have become critical in modern healthcare due to their role in managing a wide range of digestive disorders, which affect millions of people globally. These therapies are designed to treat conditions like inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), ulcers, and colorectal cancer, among others. But why are GI therapeutics so essential in today's medical landscape? Gastrointestinal diseases can significantly impact a person’s quality of life, causing pain, discomfort, malnutrition, and even life-threatening complications if left untreated. With the rising prevalence of chronic GI conditions driven by factors like diet, stress, genetics, and aging populations, the demand for effective therapies has never been higher.

GI therapeutics include a broad spectrum of treatments ranging from medications to biologics and surgical interventions. For example, proton pump inhibitors (PPIs) are commonly used to manage acid-related disorders like GERD, while immunosuppressive drugs and biologics are crucial for managing autoimmune diseases like Crohn’s disease and ulcerative colitis. The development of new therapeutics has significantly improved disease outcomes, reducing symptoms, preventing disease progression, and, in some cases, leading to remission. Given the chronic nature of many GI disorders, effective therapeutics are essential for managing symptoms, improving patient quality of life, and reducing the long-term complications associated with these conditions.

How Are Technological Advancements Revolutionizing Gastrointestinal Therapeutics?

Technological advancements are reshaping the field of gastrointestinal therapeutics, leading to more targeted, personalized, and effective treatments. One of the most transformative developments is the rise of biologic therapies. These are complex molecules, such as monoclonal antibodies, designed to target specific components of the immune system that drive inflammation in diseases like Crohn's disease and ulcerative colitis. Unlike traditional medications that suppress the immune system broadly, biologics target specific pathways, reducing inflammation with fewer side effects. Biologics have revolutionized the treatment of autoimmune gastrointestinal disorders, providing patients with longer periods of remission and reducing the need for surgery.

Gene therapy is another promising area of advancement. Research into gene-editing technologies like CRISPR has the potential to treat genetic gastrointestinal disorders by correcting mutations that lead to diseases such as cystic fibrosis or hereditary gastrointestinal cancers. Additionally, microbiome-based therapies are emerging as a novel treatment avenue. Since the gut microbiome plays a crucial role in maintaining digestive health, manipulating the balance of gut bacteria through probiotics, prebiotics, or even fecal microbiota transplants (FMT) offers a new way to treat conditions like IBS, IBD, and Clostridium difficile infections.

Furthermore, advancements in diagnostic technologies, such as capsule endoscopy and genetic testing, are improving the ability to detect GI disorders early and tailor treatments to individual patients. These personalized treatment approaches ensure that patients receive the most effective therapies based on their unique genetic and physiological makeup. Collectively, these innovations are leading to a new era of gastrointestinal therapeutics, where treatments are more precise, effective, and tailored to the specific needs of each patient.

Why Are Gastrointestinal Therapeutics Crucial for Managing Chronic Conditions?

The rising prevalence of chronic gastrointestinal conditions is one of the main reasons why gastrointestinal therapeutics are becoming increasingly important in healthcare. Conditions like Crohn’s disease, ulcerative colitis, and irritable bowel syndrome (IBS) are long-term illnesses that require ongoing management. Patients with these diseases often experience a wide range of symptoms, including abdominal pain, diarrhea, fatigue, and malnutrition, all of which can severely impact their quality of life. GI therapeutics play a crucial role in managing these symptoms, preventing disease progression, and minimizing complications, allowing patients to live healthier and more fulfilling lives.

For chronic conditions like inflammatory bowel disease (IBD), which includes Crohn's and ulcerative colitis, treatments focus on reducing inflammation and maintaining remission. Medications such as corticosteroids, immunosuppressants, and biologics are often used in combination to control flare-ups and prevent long-term damage to the gastrointestinal tract. In recent years, biologic therapies have transformed the management of IBD by providing more targeted and long-lasting relief compared to traditional treatments. These therapies block specific proteins that trigger inflammation, helping to reduce the need for surgery and hospitalizations.

Gastrointestinal therapeutics are also essential in the management of gastroesophageal reflux disease (GERD), a chronic condition where stomach acid frequently flows back into the esophagus, causing heartburn and other symptoms. If left untreated, GERD can lead to complications like esophagitis, Barrett's esophagus, or esophageal cancer. Medications like proton pump inhibitors (PPIs) and H2 receptor antagonists are commonly used to reduce stomach acid production and prevent damage to the esophagus. For patients with chronic, severe GERD, surgical interventions such as fundoplication may also be considered.

In addition to managing symptoms, gastrointestinal therapeutics are essential for preventing complications and improving long-term health outcomes in patients with chronic conditions. These treatments allow patients to achieve better disease control, reducing the burden of symptoms and improving overall quality of life.

What Factors Are Driving the Growth of the Gastrointestinal Therapeutics Market?

The growth of the gastrointestinal therapeutics market is driven by several key factors, including the increasing prevalence of GI disorders, rising demand for biologic therapies, and advancements in precision medicine. First, the global rise in gastrointestinal diseases, particularly chronic conditions like Crohn’s disease, ulcerative colitis, and GERD, is a major driver of market growth. Lifestyle factors such as poor diet, stress, and sedentary behavior are contributing to the increase in digestive disorders, and aging populations are more prone to conditions like colorectal cancer and diverticulitis. As the number of people affected by these conditions grows, the demand for effective therapeutic options is also rising.

Second, the growing adoption of biologic therapies is driving significant growth in the gastrointestinal therapeutics market. Biologics, which include monoclonal antibodies and other targeted therapies, have shown remarkable efficacy in treating inflammatory bowel diseases (IBD) and other immune-mediated conditions. These therapies are often used when traditional medications fail to provide adequate symptom control, making them a preferred option for many patients. The development of biosimilars-affordable alternatives to biologics-is further expanding access to these treatments, increasing market penetration.

Third, advancements in personalized medicine and precision therapeutics are transforming the gastrointestinal treatment landscape. Genetic testing, biomarker discovery, and microbiome analysis are enabling more tailored approaches to GI care. Patients can now receive therapies based on their individual genetic makeup or microbiome profile, leading to better outcomes and fewer side effects. This trend toward personalized medicine is increasing the demand for more targeted and innovative therapies, driving market growth.

Additionally, the rise in minimally invasive treatment options and the development of new drug delivery methods are further boosting the market. For example, capsule endoscopy and targeted drug delivery systems are improving the diagnosis and treatment of gastrointestinal conditions, reducing the need for invasive procedures. The focus on improving patient outcomes, reducing hospitalizations, and managing chronic GI conditions more effectively is fueling the expansion of gastrointestinal therapeutics.

Overall, the increasing prevalence of gastrointestinal diseases, the growing demand for biologic and personalized therapies, and ongoing advancements in medical technology are driving the robust growth of the gastrointestinal therapeutics market. As healthcare continues to focus on improving the quality of life for patients with digestive disorders, the demand for innovative and effective treatments will continue to rise.

SCOPE OF STUDY:

The report analyzes the Gastrointestinal Therapeutics market by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class, Other Drug Classes); Administration Route (Oral Administration Route, Injectables Administration Route, Other Administration Routes); Application (Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application, Other Applications); End-Use (Hospital Pharmacies End-Use, Retail Pharmacies End-Use, Online End-Use)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

SELECT PLAYERS -

• AbbVie, Inc.
• Amgen, Inc.
• Ardelyx, Inc.
• Astellas Pharma, Inc.
• AstraZeneca Plc
• Biogen, Inc.
• Eisai Co., Ltd.
• Eli Lilly and Company
• Enlivex Therapeutics Ltd.
• F. Hoffmann-La Roche Ltd.

WHAT SETS THIS REPORT APART FROM OTHERS?

Grounded in Domain Expert Perspectives - Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.

Captures Early Market Signals - Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.

Draws From a Broad, Validated Intelligence Base - Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.

Connects Signals With Strategic Market Direction - Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.

Provides In-Depth Company Intelligence - Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.

Market Share Is Examined Where It Matters - A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, Market Glass reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy
  • Global Economic Update
  • Gastrointestinal Therapeutics - Global Key Competitors Percentage Market Share in 2026 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for 44 Players Worldwide in 2026 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Gastrointestinal Disorders Globally Drives Demand for Therapeutics
  • Increasing Adoption of Biologics in Treating Inflammatory Bowel Diseases Propels Market Growth
  • Expanding Elderly Population and Associated Gastrointestinal Complications Boost Drug Demand
  • Advances in Diagnostic Techniques Improve Early Detection and Treatment Opportunities
  • Role of Microbiome Therapeutics in Revolutionizing GI Treatment Paradigms
  • Integration of Alternative and Complementary Medicines in Treatment Regimens
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Gastrointestinal Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2020 through 2032
  • TABLE 2: World Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 3: World Historic Review for Gastrointestinal Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 4: World 13-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2020, 2026 & 2032
  • TABLE 5: World Recent Past, Current & Future Analysis for Aminosalicylates Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 6: World Historic Review for Aminosalicylates Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 7: World 13-Year Perspective for Aminosalicylates Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 8: World Recent Past, Current & Future Analysis for Digestive Enzymes Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 9: World Historic Review for Digestive Enzymes Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 10: World 13-Year Perspective for Digestive Enzymes Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 11: World Recent Past, Current & Future Analysis for Proton Pump Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 12: World Historic Review for Proton Pump Inhibitors Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 13: World 13-Year Perspective for Proton Pump Inhibitors Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 14: World Recent Past, Current & Future Analysis for Laxatives Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 15: World Historic Review for Laxatives Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 16: World 13-Year Perspective for Laxatives Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 17: World Recent Past, Current & Future Analysis for Anti-Emetics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 18: World Historic Review for Anti-Emetics Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 19: World 13-Year Perspective for Anti-Emetics Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 20: World Recent Past, Current & Future Analysis for H2 Antagonists Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 21: World Historic Review for H2 Antagonists Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 22: World 13-Year Perspective for H2 Antagonists Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 23: World Recent Past, Current & Future Analysis for Anti-Diarrheals Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 24: World Historic Review for Anti-Diarrheals Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 25: World 13-Year Perspective for Anti-Diarrheals Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 26: World Recent Past, Current & Future Analysis for Biologics / Biosimilars Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 27: World Historic Review for Biologics / Biosimilars Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 28: World 13-Year Perspective for Biologics / Biosimilars Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 30: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 31: World 13-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 32: World Recent Past, Current & Future Analysis for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 33: World Historic Review for Oral Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 34: World 13-Year Perspective for Oral Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 35: World Recent Past, Current & Future Analysis for Injectables Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 36: World Historic Review for Injectables Administration Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 37: World 13-Year Perspective for Injectables Administration Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 38: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 39: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 40: World 13-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 41: World Recent Past, Current & Future Analysis for Crohn's Disease Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 42: World Historic Review for Crohn's Disease Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 43: World 13-Year Perspective for Crohn's Disease Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 44: World Recent Past, Current & Future Analysis for Ulcerative Colitis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 45: World Historic Review for Ulcerative Colitis Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 46: World 13-Year Perspective for Ulcerative Colitis Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 47: World Recent Past, Current & Future Analysis for GERD Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 48: World Historic Review for GERD Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 49: World 13-Year Perspective for GERD Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 50: World Recent Past, Current & Future Analysis for IBS Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 51: World Historic Review for IBS Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 52: World 13-Year Perspective for IBS Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 53: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 54: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 55: World 13-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 56: World Recent Past, Current & Future Analysis for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 57: World Historic Review for Hospital Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 58: World 13-Year Perspective for Hospital Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 59: World Recent Past, Current & Future Analysis for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 60: World Historic Review for Retail Pharmacies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 61: World 13-Year Perspective for Retail Pharmacies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032
  • TABLE 62: World Recent Past, Current & Future Analysis for Online End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 63: World Historic Review for Online End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 64: World 13-Year Perspective for Online End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2020, 2026 & 2032

III. MARKET ANALYSIS

• UNITED STATES
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2026 (E)
  • TABLE 65: USA Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 66: USA Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 67: USA 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 68: USA Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 69: USA Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 70: USA 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 71: USA Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 72: USA Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 73: USA 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 74: USA Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 75: USA Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 76: USA 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• CANADA
  • TABLE 77: Canada Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 78: Canada Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 79: Canada 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 80: Canada Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 81: Canada Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 82: Canada 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 83: Canada Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 84: Canada Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 85: Canada 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 86: Canada Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 87: Canada Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 88: Canada 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• JAPAN
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2026 (E)
  • TABLE 89: Japan Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 90: Japan Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 91: Japan 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 92: Japan Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 93: Japan Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 94: Japan 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 95: Japan Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 96: Japan Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 97: Japan 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 98: Japan Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 99: Japan Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 100: Japan 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• CHINA
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2026 (E)
  • TABLE 101: China Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 102: China Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 103: China 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 104: China Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 105: China Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 106: China 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 107: China Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 108: China Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 109: China 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 110: China Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 111: China Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 112: China 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• EUROPE
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2026 (E)
  • TABLE 113: Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 114: Europe Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 115: Europe 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 116: Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 117: Europe Historic Review for Gastrointestinal Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 118: Europe 13-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2020, 2026 & 2032
  • TABLE 119: Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 120: Europe Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 121: Europe 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 122: Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 123: Europe Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 124: Europe 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 125: Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 126: Europe Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 127: Europe 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• FRANCE
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2026 (E)
  • TABLE 128: France Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 129: France Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 130: France 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 131: France Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 132: France Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 133: France 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 134: France Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 135: France Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 136: France 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 137: France Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 138: France Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 139: France 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• GERMANY
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2026 (E)
  • TABLE 140: Germany Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 141: Germany Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 142: Germany 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 143: Germany Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 144: Germany Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 145: Germany 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 146: Germany Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 147: Germany Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 148: Germany 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 149: Germany Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 150: Germany Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 151: Germany 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• ITALY
  • TABLE 152: Italy Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 153: Italy Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 154: Italy 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 155: Italy Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 156: Italy Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 157: Italy 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 158: Italy Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 159: Italy Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 160: Italy 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 161: Italy Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 162: Italy Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 163: Italy 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• UNITED KINGDOM
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2026 (E)
  • TABLE 164: UK Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 165: UK Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 166: UK 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 167: UK Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 168: UK Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 169: UK 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 170: UK Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 171: UK Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 172: UK 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 173: UK Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 174: UK Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 175: UK 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• SPAIN
  • TABLE 176: Spain Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 177: Spain Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 178: Spain 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 179: Spain Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 180: Spain Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 181: Spain 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 182: Spain Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 183: Spain Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 184: Spain 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 185: Spain Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 186: Spain Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 187: Spain 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• RUSSIA
  • TABLE 188: Russia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 189: Russia Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 190: Russia 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 191: Russia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 192: Russia Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 193: Russia 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 194: Russia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 195: Russia Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 196: Russia 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 197: Russia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 198: Russia Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 199: Russia 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• REST OF EUROPE
  • TABLE 200: Rest of Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 201: Rest of Europe Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 202: Rest of Europe 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 203: Rest of Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 204: Rest of Europe Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 205: Rest of Europe 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 206: Rest of Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 207: Rest of Europe Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 208: Rest of Europe 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 209: Rest of Europe Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 210: Rest of Europe Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 211: Rest of Europe 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• ASIA-PACIFIC
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2026 (E)
  • TABLE 212: Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 213: Asia-Pacific Historic Review for Gastrointestinal Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 214: Asia-Pacific 13-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2020, 2026 & 2032
  • TABLE 215: Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 216: Asia-Pacific Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 217: Asia-Pacific 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 218: Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 219: Asia-Pacific Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 220: Asia-Pacific 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 221: Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 222: Asia-Pacific Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 223: Asia-Pacific 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
  • TABLE 224: Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 225: Asia-Pacific Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 226: Asia-Pacific 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
• AUSTRALIA
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2026 (E)
  • TABLE 227: Australia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 228: Australia Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 229: Australia 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 230: Australia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 231: Australia Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 232: Australia 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 233: Australia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 234: Australia Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 235: Australia 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
  • TABLE 236: Australia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 237: Australia Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 238: Australia 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
• INDIA
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2026 (E)
  • TABLE 239: India Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 240: India Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 241: India 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 242: India Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 243: India Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 244: India 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 245: India Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 246: India Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 247: India 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
  • TABLE 248: India Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 249: India Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 250: India 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
• SOUTH KOREA
  • TABLE 251: South Korea Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 252: South Korea Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 253: South Korea 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 254: South Korea Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 255: South Korea Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 256: South Korea 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 257: South Korea Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 258: South Korea Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 259: South Korea 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
  • TABLE 260: South Korea Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 261: South Korea Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 262: South Korea 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
• REST OF ASIA-PACIFIC
  • TABLE 263: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 264: Rest of Asia-Pacific Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 265: Rest of Asia-Pacific 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 266: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 267: Rest of Asia-Pacific Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 268: Rest of Asia-Pacific 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 269: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 270: Rest of Asia-Pacific Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 271: Rest of Asia-Pacific 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
  • TABLE 272: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 273: Rest of Asia-Pacific Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 274: Rest of Asia-Pacific 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
• LATIN AMERICA
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2026 (E)
  • TABLE 275: Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 276: Latin America Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 277: Latin America 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 278: Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 279: Latin America Historic Review for Gastrointestinal Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 280: Latin America 13-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2020, 2026 & 2032
  • TABLE 281: Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 282: Latin America Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 283: Latin America 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 284: Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 285: Latin America Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 286: Latin America 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 287: Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 288: Latin America Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 289: Latin America 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• ARGENTINA
  • TABLE 290: Argentina Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 291: Argentina Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 292: Argentina 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 293: Argentina Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 294: Argentina Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 295: Argentina 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 296: Argentina Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 297: Argentina Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 298: Argentina 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 299: Argentina Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 300: Argentina Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 301: Argentina 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• BRAZIL
  • TABLE 302: Brazil Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 303: Brazil Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 304: Brazil 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 305: Brazil Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 306: Brazil Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 307: Brazil 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 308: Brazil Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 309: Brazil Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 310: Brazil 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 311: Brazil Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 312: Brazil Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 313: Brazil 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• MEXICO
  • TABLE 314: Mexico Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 315: Mexico Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 316: Mexico 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 317: Mexico Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 318: Mexico Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 319: Mexico 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 320: Mexico Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 321: Mexico Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 322: Mexico 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 323: Mexico Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 324: Mexico Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 325: Mexico 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• REST OF LATIN AMERICA
  • TABLE 326: Rest of Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 327: Rest of Latin America Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 328: Rest of Latin America 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 329: Rest of Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 330: Rest of Latin America Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 331: Rest of Latin America 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 332: Rest of Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 333: Rest of Latin America Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 334: Rest of Latin America 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 335: Rest of Latin America Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 336: Rest of Latin America Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 337: Rest of Latin America 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• MIDDLE EAST
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2026 (E)
  • TABLE 338: Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 339: Middle East Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 340: Middle East 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 341: Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2025 through 2032 and % CAGR
  • TABLE 342: Middle East Historic Review for Gastrointestinal Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 343: Middle East 13-Year Perspective for Gastrointestinal Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2020, 2026 & 2032
  • TABLE 344: Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 345: Middle East Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 346: Middle East 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 347: Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 348: Middle East Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 349: Middle East 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 350: Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 351: Middle East Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 352: Middle East 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• IRAN
  • TABLE 353: Iran Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 354: Iran Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 355: Iran 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 356: Iran Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 357: Iran Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 358: Iran 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 359: Iran Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 360: Iran Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 361: Iran 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 362: Iran Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 363: Iran Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 364: Iran 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• ISRAEL
  • TABLE 365: Israel Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 366: Israel Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 367: Israel 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 368: Israel Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 369: Israel Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 370: Israel 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 371: Israel Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 372: Israel Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 373: Israel 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 374: Israel Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 375: Israel Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 376: Israel 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• SAUDI ARABIA
  • TABLE 377: Saudi Arabia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 378: Saudi Arabia Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 379: Saudi Arabia 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 380: Saudi Arabia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 381: Saudi Arabia Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 382: Saudi Arabia 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 383: Saudi Arabia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 384: Saudi Arabia Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 385: Saudi Arabia 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 386: Saudi Arabia Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 387: Saudi Arabia Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 388: Saudi Arabia 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• UNITED ARAB EMIRATES
  • TABLE 389: UAE Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 390: UAE Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 391: UAE 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 392: UAE Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 393: UAE Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 394: UAE 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 395: UAE Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 396: UAE Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 397: UAE 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 398: UAE Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 399: UAE Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 400: UAE 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• REST OF MIDDLE EAST
  • TABLE 401: Rest of Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 402: Rest of Middle East Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 403: Rest of Middle East 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 404: Rest of Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 405: Rest of Middle East Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 406: Rest of Middle East 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 407: Rest of Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 408: Rest of Middle East Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 409: Rest of Middle East 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 410: Rest of Middle East Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 411: Rest of Middle East Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 412: Rest of Middle East 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032
• AFRICA
  • Gastrointestinal Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2026 (E)
  • TABLE 413: Africa Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 414: Africa Historic Review for Gastrointestinal Therapeutics by End-Use - Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 415: Africa 13-Year Perspective for Gastrointestinal Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospital Pharmacies End-Use, Retail Pharmacies End-Use and Online End-Use for the Years 2020, 2026 & 2032
  • TABLE 416: Africa Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 417: Africa Historic Review for Gastrointestinal Therapeutics by Drug Class - Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 418: Africa 13-Year Perspective for Gastrointestinal Therapeutics by Drug Class - Percentage Breakdown of Value Sales for Aminosalicylates Drug Class, Digestive Enzymes Drug Class, Proton Pump Inhibitors Drug Class, Laxatives Drug Class, Anti-Emetics Drug Class, H2 Antagonists Drug Class, Anti-Diarrheals Drug Class, Biologics / Biosimilars Drug Class and Other Drug Classes for the Years 2020, 2026 & 2032
  • TABLE 419: Africa Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 420: Africa Historic Review for Gastrointestinal Therapeutics by Administration Route - Oral Administration Route, Injectables Administration Route and Other Administration Routes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 421: Africa 13-Year Perspective for Gastrointestinal Therapeutics by Administration Route - Percentage Breakdown of Value Sales for Oral Administration Route, Injectables Administration Route and Other Administration Routes for the Years 2020, 2026 & 2032
  • TABLE 422: Africa Recent Past, Current & Future Analysis for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2025 through 2032 and % CAGR
  • TABLE 423: Africa Historic Review for Gastrointestinal Therapeutics by Application - Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2024 and % CAGR
  • TABLE 424: Africa 13-Year Perspective for Gastrointestinal Therapeutics by Application - Percentage Breakdown of Value Sales for Crohn's Disease Application, Ulcerative Colitis Application, GERD Application, IBS Application and Other Applications for the Years 2020, 2026 & 2032

IV. COMPETITION